Population-Scale Discovery of Clinical and Genomic Determinants of Systematic Therapy Adverse Events in Patients with Solid Tumors
Almost every patient with cancer who is treated with systemic therapy will develop at least one adverse event (AE), and up to half of patients develop severe AEs, leading to hospitalization, critical illness requiring intensive care unit level care, or death. Despite the burden of AEs, our understanding of their patterns of development as well as their clinical and genomic correlates has critically lagged behind biomarker development for cancer therapy responses. Here, we propose to comprehensively define the incidence and etiology of AEs across the major classes of systemic therapies (chemotherapy, targeted therapies, and immune checkpoint inhibitors [ICIs]) at population-scale. To do so, we will combine the constellation of rich clinical and genomic data available for patients at Memorial Sloan Kettering Cancer Center with unique expertise in natural language processing, systematically leveraging data from across cancer types to enable clinical and translational discoveries about AEs. This work would ultimately enable predictive modeling of adverse events and allow physicians to inform and mitigate risks of systemic therapies to patient